Abstract
Introduction There is a continuing need for improved drugs for treatment and prevention of malaria. Drugs with causal prophylactic activity are especially useful for prevention of malaria in individuals with a limited duration of exposure in a malaria-endemic area. In this paper I compare the requirements for causal prophylaxis of relapsing and non-relapsing malarias and review some of the challenges to the development of new prophylactic antimalarial drugs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Transactions of the Royal Society of Tropical Medicine and Hygiene
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
